At CellSync Biosciences, we’re pioneering next-generation technologies to transform how cell and gene therapies are developed and delivered. Our goal is to make advanced personalised treatments faster, scalable, and within reach for patients worldwide.
CellSync Biosciences is a next-generation biotechnology company advancing the way cell and gene therapies are developed and manufactured. Our work focuses on leveraging innovations to create highly efficient, scalable, and precise solutions for cell engineering and delivering genetic material to target cells.
To drive the advancement of cell and gene therapy platforms by developing high-throughput, scalable solutions that empower scientists and enhance manufacturing efficiency, and accelerate the delivery of life-changing treatments to patients worldwide.
We envision a future where genetic therapies are no longer experimental or limited to a select few but are safe, reliable, and accessible to every individual in need—transforming the standard of care across the globe.
We are open to collaborate with scientists, therapeutic developers, and manufacturing teams to overcome long-standing bottlenecks in cell and gene therapy workflows. By introducing novel technologies that improve speed, consistency, and cost-efficiency, we are helping pave the way for a new era in genetic medicine-one where transformative therapies reach patients faster and at a global scale.
Current methods for engineering immune cells rely heavily on viral vectors or electroporation, which can be:
Expensive and time-intensive
Inconsistent in transfection rates
Harmful to cell viability
Difficult to scale for clinical manufacturing
As demand for cell therapies grows, existing platforms cannot meet the required speed, safety, or scalability.
CellSync Biosciences replaces outdated delivery systems with a non-viral platform that enables:
High-throughput, automated cell engineering
Enhanced cell viability and recovery rates
Cost-effective and scalable manufacturing
Greater consistency across batches
Our platform empowers therapeutic developers to produce smarter, stronger immune cells, faster and at scale
Dr. Dorsa Rad is a scientist, entrepreneur, and passionate advocate for transforming cell and gene therapy manufacturing. With deep expertise in biomedical engineering and translational research, she co-founded CellSync Biosciences to address long-standing inefficiencies in cell engineering platforms. Her vision is rooted in making high-quality therapies accessible for patients worldwide.
Stay up to date with the latest innovations, scientific insights, and industry trends driving the future of cell engineering and genetic medicine.
